Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Long-Term Investments (2017 - 2025)

Historic Long-Term Investments for Denali Therapeutics (DNLI) over the last 9 years, with Q3 2025 value amounting to $24.7 million.

  • Denali Therapeutics' Long-Term Investments fell 9445.45% to $24.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.7 million, marking a year-over-year decrease of 9445.45%. This contributed to the annual value of $359.4 million for FY2024, which is N/A changed from last year.
  • Denali Therapeutics' Long-Term Investments amounted to $24.7 million in Q3 2025, which was down 9445.45% from $78.5 million recorded in Q2 2025.
  • Over the past 5 years, Denali Therapeutics' Long-Term Investments peaked at $490.7 million during Q1 2024, and registered a low of $7.9 million during Q3 2023.
  • Over the past 5 years, Denali Therapeutics' median Long-Term Investments value was $243.1 million (recorded in 2022), while the average stood at $236.7 million.
  • As far as peak fluctuations go, Denali Therapeutics' Long-Term Investments skyrocketed by 553520.56% in 2024, and later tumbled by 9445.45% in 2025.
  • Quarter analysis of 5 years shows Denali Therapeutics' Long-Term Investments stood at $425.4 million in 2021, then crashed by 77.85% to $94.2 million in 2022, then plummeted by 91.61% to $7.9 million in 2023, then soared by 4446.15% to $359.4 million in 2024, then crashed by 93.13% to $24.7 million in 2025.
  • Its Long-Term Investments stands at $24.7 million for Q3 2025, versus $78.5 million for Q2 2025 and $235.8 million for Q1 2025.